Trials / Completed

CompletedNCT00297687

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 108 (planned)

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex: All
Age: 18 Years – 25 Years
Healthy volunteers: Accepted

Summary

To determine the safety \& immunogenicity of a potential vaccine against meningococcal B disease

Conditions

Meningitis, Meningococcal

Interventions

Type	Name	Description
BIOLOGICAL	MnB rLP2086

Timeline

Start date: 2006-03-01
Completion: 2007-03-01
First posted: 2006-02-28
Last updated: 2007-12-05

Locations

3 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT00297687. Inclusion in this directory is not an endorsement.